CIK: 0001687078 · Show all filings
Period: Q4 2021 (← Previous) (Next →)
Filing Date: Feb 11, 2022
Total Value ($000): $548,527 (100.0% shares, 0.0% debt)
| Ticker | Issuer | Shares | Value ($000) | % | Est. Cost | Unrealized | Class | CUSIP |
|---|---|---|---|---|---|---|---|---|
| CGEM | Cullinan Oncology, Inc. | 7,648,268 | $118,013 | 21.5% | $40.60 | -50.9% | Common | 230031106 |
| — | iTeos Therapeutics, Inc. | 1,844,727 | $85,890 | 15.7% | $24.67 | — | Common | 46565G104 |
| — | Repare Therapeutics, Inc. | 1,639,849 | $34,584 | 6.3% | $31.02 | — | Common | 760273102 |
| — | MEI Pharma, Inc. | 12,350,971 | $32,977 | 6.0% | $2.67 | — | Common | 55279B202 |
| — | Merus N.V. | 927,302 | $29,488 | 5.4% | $17.60 | — | Common | N5749R100 |
| HOWL | Werewolf Therapeutics, Inc. | 2,388,011 | $28,441 | 5.2% | $13.70 | +10.2% | Common | 95075A107 |
| — | Harpoon Therapeutics, Inc. | 3,196,707 | $24,135 | 4.4% | $14.79 | — | Common | 41358P106 |
| NTLA | Intellia Therapeutics, Inc. | 160,527 | $18,981 | 3.5% | $151.40 | -17.3% | Common | 45826J105 |
| — | TCR2 Therapeutics, Inc. | 3,370,982 | $15,709 | 2.9% | $14.28 | — | Common | 87808K106 |
| — | Turning Point Therapeutics, Inc. | 271,350 | $12,943 | 2.4% | $44.66 | — | Common | 90041T108 |
| — | Oncorus, Inc. | 2,377,031 | $12,527 | 2.3% | $32.33 | — | Common | 68236R103 |
| CRNX | Crinetics Pharmaceuticals Inc. | 379,792 | $10,790 | 2.0% | $21.72 | +13.5% | Common | 22663K107 |
| CYTK | Cytokinetics Inc. | 232,268 | $10,587 | 1.9% | $29.44 | +31.1% | Common | 23282W605 |
| — | ESSA Pharma, Inc. | 668,688 | $9,495 | 1.7% | $8.00 | — | Common | 29668H708 |
| BCRX | Biocryst Pharmaceuticals Inc. | 661,951 | $9,168 | 1.7% | $15.77 | -16.1% | Common | 09058V103 |
| TVTX | Travere Therapeutics Inc. | 287,893 | $8,936 | 1.6% | $18.37 | +53.3% | Common | 89422G107 |
| — | G1 Therapeutics, Inc. | 856,798 | $8,748 | 1.6% | $25.71 | — | Common | 3621LQ109 |
| — | Epizyme, Inc. | 3,425,202 | $8,563 | 1.6% | $15.19 | — | Common | 29428V104 |
| — | YmAbs Therapeutics, Inc. | 446,457 | $7,237 | 1.3% | $30.56 | — | Common | 984241109 |
| GERN | Geron Corporation | 5,623,889 | $6,861 | 1.3% | $1.33 | +7.3% | Common | 374163103 |
| ADCT | ADC Therapeutics, Inc. | 337,396 | $6,815 | 1.2% | $33.59 | -28.2% | Common | H0036K147 |
| — | Verastem, Inc. | 3,271,532 | $6,707 | 1.2% | $2.94 | — | Common | 92337C104 |
| HRMY | Harmony Biosciences Hldgs Inc. | 142,437 | $6,074 | 1.1% | $32.20 | +23.8% | Common | 413197104 |
| FOLD | Amicus Therapeutics Inc. | 513,333 | $5,929 | 1.1% | $10.23 | +8.9% | Common | 03152W109 |
| NEO | Neogenomics Inc. | 140,422 | $4,791 | 0.9% | $46.29 | -15.4% | Common | 64049M209 |
| MIRM | Mirum Pharmaceuticals Inc. | 298,852 | $4,767 | 0.9% | $16.26 | -4.4% | Common | 604749101 |
| AXSM | Axsome Therapeutics Inc. | 103,405 | $3,907 | 0.7% | $38.97 | -5.6% | Common | 05464T104 |
| RVMD | Revolution Medicines, Inc. | 146,041 | $3,676 | 0.7% | $29.11 | -3.2% | Common | 76155X100 |
| — | Avadel Pharmaceuticals Plc | 375,326 | $3,033 | 0.6% | $9.80 | — | Common | 05337M104 |
| ACAD | Acadia Pharmaceuticals Inc | 125,000 | $2,918 | 0.5% | $20.11 | 0.0% | Common | 004225108 |
| — | AVROBIO, Inc. | 647,918 | $2,494 | 0.5% | $5.58 | — | Common | 05455M100 |
| — | Inozyme Pharma Inc. | 302,615 | $2,064 | 0.4% | $11.59 | — | Common | 45790W108 |
| BDTX | Black Diamond Therapeutics, Inc. | 239,888 | $1,279 | 0.2% | $9.87 | -29.3% | Common | 09203E105 |